Sign in
Taking people in New ZealandPhase 3

Compares two chest surgeries for bone cancer that has spread to the lungs

Compares open chest surgery with keyhole surgery in people with osteosarcoma spread to lungs.

Key facts

Who runs it
Children's Oncology Group
Where
Christchurch and Grafton, New ZealandSee the 2 sitesAlso in 5 other countries, 231 sites
Trial code
Registry title
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Status
Recruiting
Phase
Phase 3
People taking part
62 people, planned
Started
1 Apr 2022
Expected to end
31 Mar 2031
Type of study
Interventional, 2 groups
Treatments tested
  • Biospecimen Collection
  • Computed Tomography
  • Questionnaire Administration
  • Thoracoscopy
  • Thoracotomy
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people under 50 with osteosarcoma that has spread to the lungs, where the lung spots can be removed by surgery. It compares open chest surgery with keyhole (thoracoscopic) surgery.

Age
Under 50 years.
Sex
All sexes can join.
Disease stage
Osteosarcoma (confirmed by tissue test) that has spread to the lungs, found at first diagnosis or at the first return of the cancer. Up to 4 lung spots per lung, at least one 3 mm or larger, all 3 cm (1.2 in) or smaller. The spots must be removable by open or thoracoscopic surgery.
Earlier treatment
People newly diagnosed must be having, or have finished within 60 days, standard drug treatment for osteosarcoma, with the main tumor removed or removal planned together with the chest surgery. People at first return of the cancer must have finished standard drug treatment for the first tumor. No earlier lung surgery for the spread.

Main reasons for not taking part

  • Primary tumor that cannot be removed by surgery
  • Lung spots needing removal of a lobe or a whole lung, or spots in the central part of the lung
  • Spots in the chest wall or the middle of the chest, or a lot of fluid around the lung
  • Cancer that grew during first treatment, or cancer spread outside the lungs
  • Earlier lung surgery for the spread

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients must be < 50 years at the time of enrollment
  • Patients must have =< 4 nodules per lung consistent with or suspicious for metastases, with at least one of which being >= 3 mm and all of which must be =< 3 cm size; Note: Patient must have eligibility confirmed by rapid central imaging review
  • Lung nodules must be considered resectable by either open thoracotomy or thoracoscopic surgery. Determination of resectability is made by the institutional surgeon
  • Patients must have a histological diagnosis of osteosarcoma
  • Patients must have evidence of metastatic lung disease at the time of initial diagnosis, or at time of 1st recurrence following completion of therapy for initially localized disease
  • Patients with newly diagnosed disease must have completed successful gross tumor resection for their primary tumor or surgical local control of primary tumor must be planned to be performed simultaneously with thoracic surgery
  • Newly diagnosed patients must be receiving or recently completed (within 60 days) systemic therapy considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation
  • Patients at time of 1st recurrence must have completed systemic therapy for their initial primary tumor, considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation

Who cannot take part

  • Patients with pulmonary metastatic lesions that would require anatomic resection (lobectomy or pneumonectomy) or lesions that are defined as "central" (i.e., central lesion involves or is proximal to segmental bronchi and peripheral is lesion distal to segmental bronchi)
  • Patients with disease progression at either the primary or pulmonary metastatic site while on initial therapy. Note: Once the patient has been enrolled on the study, additional computed tomography (CT) scans are not anticipated prior to thoracic surgery. Note: Some variation in nodule size measurements over the course of pre-operative therapy is anticipated and does not qualify for exclusion unless deemed true disease progression by the primary treatment team
  • Patients who received therapeutic pulmonary surgery for lung metastasis prior to enrollment
  • Patients with evidence of extrapulmonary metastatic disease
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
  • Patients with unresectable primary tumor
  • Patients with chest wall or mediastinal based metastatic lesions, or with significant pleural effusion
  • All patients and/or their parents or legal guardians must sign a written informed consent

This trial is currently available in New Zealand.

Also in 5 other countries, 231 sites

  • Christchurch HospitalChristchurch, New ZealandContact: Tristan Pettit (principal investigator)Taking people
  • Starship Children's HospitalGrafton, New ZealandContact: Mandy PohLui de Silva (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

The 2 groups in the trial

  • Arm A (thoracotomy)Treatment being tested

    Patients undergo open thoracic surgery (thoracotomy). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.

    Treatment: Biospecimen Collection, Computed Tomography, Questionnaire Administration, and Thoracotomy

  • Arm B (thoracoscopy)Treatment being tested

    Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.

    Treatment: Biospecimen Collection, Questionnaire Administration, and Thoracoscopy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Plain-language title
Compares two chest surgeries for bone cancer that has spread to the lungsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 August 2026